Addendum re Lovenox doses in FDA label: I would argue that the distinctions between the various VTE-prevention cases are more arbitrary than scientific. Moreover, in the hip/knee case, the “switchover” regimen of 30mg BID initially and then 40mg qD has never been tested in a RCT versus 40mg qD throughout the treatment period. I doubt that the switchover regimen is genuinely superior in terms of a composite of safety (bleeding) and efficacy.
Market Data 
Markets 
AI
